Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure

por Satapathy, Sanjaya K., Sundaram, Vinay, Shiffman, Mitchell L., Jamieson, Brian D.
Publicado 2023

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C

por Flisiak, Robert, Shiffman, Mitchell, Arenas, Juan, Cheinquer, Hugo, Nikitin, Igor, Dong, Yuping, Rana, Khurram, Srinivasan, Subasree
Publicado 2016

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin

por Asselah, Tarik, Thompson, Alex J., Flisiak, Robert, Romero-Gomez, Manuel, Messinger, Diethelm, Bakalos, Georgios, Shiffman, Mitchell L.
Publicado 2016

Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease

por Shiffman, Mitchell, Freilich, Bradley, Vuppalanchi, Raj, Watt, Kymberly, Chan, Jean L., Spada, Al, Hagerty, David T., Schiff, Eugene
Publicado 2018

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis

por Parés, Albert, Shiffman, Mitchell, Vargas, Victor, Invernizzi, Pietro, Malecha, Elizabeth S., Liberman, Alexander, MacConell, Leigh, Hirschfield, Gideon
Publicado 2020

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents

por Shiffman, Mitchell L, Rustgi, Vinod, Bennett, Michael, Forns, Xavier, Asselah, Tarik, Planas Vila, Ramon, Liu, Li, Pedrosa, Marcos, Moller, Jonathan, Reau, Nancy
Publicado 2016

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort

por Foster, Graham R., Coppola, Carmine, Derbala, Moutaz, Ferenci, Peter, Orlandini, Alessandra, Reddy, K. Rajender, Tallarico, Ludovico, Shiffman, Mitchell L., Ahlers, Silke, Bakalos, Georgios, Hassanein, Tarek
Publicado 2016

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/...

por Gane, Edward, de Ledinghen, Victor, Dylla, Douglas E., Rizzardini, Giuliano, Shiffman, Mitchell L., Barclay, Stephen T., Calleja, Jose Luis, Xue, Zhenyi, Burroughs, Margaret, Gutierrez, Julio A.
Publicado 2021

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

por Forns, Xavier, Poordad, Fred, Pedrosa, Marcos, Berenguer, Marina, Wedemeyer, Heiner, Ferenci, Peter, Shiffman, Mitchell L., Fried, Michael W., Lovell, Sandra, Trinh, Roger, Lopez‐Talavera, Juan Carlos, Everson, Gregory
Publicado 2015

309 Quantitative tests (QLFTS) detect impaired hepatic function in a high proportion of chronic hepatitis C patients with fibrosis or compensated cirrhosis and may predict risk of...

por Everson, Gregory T., Kugelmas, Marcelo, DeSantos, Jennifer, Lauriski, Shannon, Shiffman, Mitchell L., Sterling, Richard, Charlotte, Hofmann, Morgan, Timothy, Hoefs, John, Milne, Nora, Rietkerk, William, Wagner, David, Wright, Elizabeth
Publicado 2003

An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C

por O'Brien, Thomas R., Everhart, James E., Morgan, Timothy R., Lok, Anna S., Chung, Raymond T., Shao, Yongwu, Shiffman, Mitchell L., Dotrang, Myhanh, Sninsky, John J., Bonkovsky, Herbert L., Pfeiffer, Ruth M.
Publicado 2011

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis

por Flamm, Steven, Lawitz, Eric, Borg, Brian, Charlton, Michael, Landis, Charles, Reddy, K. Rajender, Shiffman, Mitchell, Alsina, Angel, Chang, Charissa, Ravendhran, Natarajan, Hernandez, Candido, Hézode, Christophe, Scherbakovsky, Stacey, Mercier, Renee-Claude, Samuel, Didier
Publicado 2023

Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension

por Garcia‐Tsao, Guadalupe, Fuchs, Michael, Shiffman, Mitchell, Borg, Brian B., Pyrsopoulos, Nikolaos, Shetty, Kirti, Gallegos‐Orozco, Juan F., Reddy, K. Rajender, Feyssa, Eyob, Chan, Jean L., Yamashita, Mason, Robinson, James M., Spada, Alfred P., Hagerty, David T., Bosch, Jaime
Publicado 2018

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection

por Sarrazin, Christoph, Castelli, Francesco, Andreone, Pietro, Buti, Maria, Colombo, Massimo, Pol, Stanislas, Calinas, Filipe, Puoti, Massimo, Olveira, Antonio, Shiffman, Mitchell, Stern, Jerry O, Kukolj, George, Roehrle, Michael, Aslanyan, Stella, Deng, Qiqi, Vinisko, Richard, Mensa, Federico J, Nelson, David R
Publicado 2016

Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data

por Wilder, Julius M., Jeffers, Lennox J., Ravendhran, Natarajan, Shiffman, Mitchell L., Poulos, John, Sulkowski, Mark S., Gitlin, Norman, Workowski, Kimberly, Zhu, Yanni, Yang, Jenny C., Pang, Phillip S., McHutchison, John G., Muir, Andrew J., Howell, Charles, Kowdley, Kris, Afdhal, Nezam, Reddy, K. Rajender
Publicado 2015

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

por Younossi, Zobair M., Stepanova, Maria, Noureddin, Mazen, Kowdley, Kris V., Strasser, Simone I., Kohli, Anita, Ruane, Peter, Shiffman, Mitchell L., Sheikh, Aasim, Gunn, Nadege, Caldwell, Stephen H., Huss, Ryan S., Myers, Robert P., Wai‐Sun Wong, Vincent, Alkhouri, Naim, Goodman, Zachary, Loomba, Rohit
Publicado 2021

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

por Trauner, Michael, Gulamhusein, Aliya, Hameed, Bilal, Caldwell, Stephen, Shiffman, Mitchell L., Landis, Charles, Eksteen, Bertus, Agarwal, Kosh, Muir, Andrew, Rushbrook, Simon, Lu, Xiaomin, Xu, Jun, Chuang, Jen‐Chieh, Billin, Andrew N., Li, Georgia, Chung, Chuhan, Subramanian, G. Mani, Myers, Robert P., Bowlus, Christopher L., Kowdley, Kris V.
Publicado 2019

A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study

por Sulkowski, Mark S., Moon, Juhi S., Sherman, Kenneth E., Morelli, Giuseppe, Darling, Jama M., Muir, Andrew J., Khalili, Mandana, Fishbein, Dawn A., Hinestrosa, Federico, Shiffman, Mitchell L., Di Bisceglie, Adrian, Reddy, K. Rajender, Pearlman, Brian, Lok, Anna S., Fried, Michael W., Stewart, Paul W., Peter, Joy, Wadsworth, Summer, Kixmiller, Scott, Sloan, Anquenette, Vainorius, Monika, Horne, Patrick M., Michael, Larry, Dong, Meichen, Evon, Donna M., Segal, Jodi B., Nelson, David R.
Publicado 2021

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

por Hirschfield, Gideon M., Shiffman, Mitchell L., Gulamhusein, Aliya, Kowdley, Kris V., Vierling, John M., Levy, Cynthia, Kremer, Andreas E., Zigmond, Ehud, Andreone, Pietro, Gordon, Stuart C., Bowlus, Christopher L., Lawitz, Eric J., Aspinall, Richard J., Pratt, Daniel S., Raikhelson, Karina, Gonzalez-Huezo, Maria S., Heneghan, Michael A., Jeong, Sook-Hyang, Ladrón de Guevara, Alma L., Mayo, Marlyn J., Dalekos, George N., Drenth, Joost P.H., Janczewska, Ewa, Leggett, Barbara A., Nevens, Frederik, Vargas, Victor, Zuckerman, Eli, Corpechot, Christophe, Fassio, Eduardo, Hinrichsen, Holger, Invernizzi, Pietro, Trivedi, Palak J., Forman, Lisa, Jones, David E.J., Ryder, Stephen D., Swain, Mark G., Steinberg, Alexandra, Boudes, Pol F., Choi, Yun-Jung, McWherter, Charles A.
Publicado 2023